Core Event: Merck's Double Delight as Keytruda Advances Further
On the weekend of August 2, 2026, the US dividend pharma sector received a strong boost. Global pharmaceutical giant Merck & Co. (MRK) announced two major positives after Friday's market close: First, the U.S. Food and Drug Administration (FDA) officially approved the subcutaneous injection formulation of its blockbuster PD-1 inhibitor Keytruda (pembrolizumab) for adjuvant treatment of patients with resectable non-small cell lung cancer (NSCLC). Second, the company's board declared an 8% increase in the quarterly dividend, raising it from $0.81 to $0.875 per share. This one-two punch not only significantly boosted market confidence in the lifecycle management of Merck's core product but also reaffirmed the dual-engine logic of 'innovative drug approval + high dividend' driving US dividend pharma plays.
Subcutaneous Formulation Approval: Extending Keytruda's Commercial Moat
For long-term investors focused on US dividend pharma, Keytruda's patent cliff has long been a sword of Damocles hanging over Merck. The approval of this subcutaneous formulation is a critical step for Merck to extend exclusivity through formulation innovation. Compared to traditional intravenous infusion, subcutaneous injection can shorten administration time from 30-60 minutes to just 2-3 minutes, greatly improving patient treatment experience and healthcare resource utilization.
On a deeper level, this formulation improvement provides Merck with a clear pathway for patent extension. As the intravenous formulation patents face expiration risk in 2028, the new patent portfolio for the subcutaneous formulation will effectively fend off biosimilar competition. According to information disclosed in the FDA Orange Book, the new formulation has secured composition-of-matter patent protection until 2040, creating a solid barrier to lock in Keytruda's ultra-high gross margins for over a decade. With Keytruda's global sales surpassing $30 billion in 2025, Wall Street analysts generally predict that the subcutaneous formulation could raise peak sales estimates to $35 billion.
8% Dividend Hike: A Hardcore Delivery on High-Dividend Strategy
Merck's increase of its quarterly dividend to $0.87 marks the company's 12th consecutive year of dividend growth. Based on the current stock price, Merck's forward dividend yield has climbed to around 3.8%, ranking among the top in the S&P 500 pharmaceutical stocks. This move is not only a commitment to shareholder returns but also reflects management's extreme confidence in the cash flow generated after the launch of Keytruda's subcutaneous formulation.
Looking at the Q2 2026 earnings report, Merck holds $15 billion in cash and equivalents, with operating cash flow exceeding $22 billion, fully supporting its capacity for sustained high payouts. Against the backdrop of the Federal Reserve maintaining high interest rates and heightened market volatility, stocks with such defensive growth and stable dividend characteristics are becoming the preferred safe-haven assets. This explains why Merck's stock price surged nearly 4% in after-hours trading following the announcement, lifting the entire US dividend pharma sector.
Industry Ripple Effect: Valuation Repair Logic in the Biopharma Sector
Merck's positive news is not an isolated event. Recently, US dividend pharma has consistently attracted capital attention, with the core logic being: In a high-interest-rate environment, blue-chip pharma stocks with strong cash flow and stable dividend payments are seeing their defensive value re-priced. From AbbVie's Q2 earnings beat and increased investment in AI-driven drug discovery, to Johnson & Johnson's dividend hike combined with new drug approvals, and now Merck's 'drug + dividend' combination, large biopharmaceutical companies are responding to patent cliff concerns with solid performance and dividend policies.
Notably, the approval of the subcutaneous formulation also benefits related drug delivery device and contract development and manufacturing organization (CDMO) companies. For instance, West Pharmaceutical Services (WST), which supplies pre-filled syringe components to Merck, and Catalent (CTLT), which handles part of the fill-finish operations, saw their stock prices rise in tandem during after-hours trading.
Allocation Advice: Focus on 'Cash Cows' and Pipeline Depth
For current investors in US dividend pharma, simple 'high dividend' screening is no longer sufficient to navigate the complex regulatory environment. We recommend a refined allocation approach based on three dimensions:
- Formulation Innovation for Core Patents: Look for products that extend their lifecycle through secondary innovations like subcutaneous injections or long-acting formulations, similar to Merck's strategy.
- Cash Flow and Payout Ratio: Prioritize targets with a free cash flow/dividend coverage ratio above 2x and a dividend yield exceeding 3% to ensure dividend sustainability.
- Pipeline Depth and AI Integration: While maintaining a dividend-focused core, consider moderate allocation to companies like AbbVie that actively embrace AI-driven drug discovery and offer future growth potential.
Looking ahead, as the FDA's accelerated approval pathway becomes routine and biosimilar competition intensifies, leading pharmaceutical companies with strong commercialization capabilities and differentiated formulation technologies will continue to act as ballast in the US dividend pharma sector. Merck's latest breakthrough undoubtedly provides a new catalyst for the upward shift in the sector's overall valuation.
